Literature DB >> 32183947

It's All About MEis: Menin-MLL Inhibition Eradicates NPM1-Mutated and MLL-Rearranged Acute Leukemias in Mice.

Michael C Gundry1, Margaret A Goodell2, Lorenzo Brunetti3.   

Abstract

Several acute myeloid leukemia genetic sub-types converge on high expression of HOX genes, critical for their self-renewal. A new orally bioavailable Menin-MLL inhibitor (VTP-50469) appears to promote their differentiation through direct effects on the HOX cofactor MEIS1, paving the way for clinical trials.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID： 32183947     DOI： 10.1016/j.ccell.2020.02.011

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  6 in total

1.  The antagonistic duality of NPM1 mutations in AML.

Authors:  Irum Khan; Andrei L Gartel
Journal:  Blood Adv       Date:  2022-07-12

2.  Mapping the native interaction surfaces of PREP1 with PBX1 by cross-linking mass-spectrometry and mutagenesis.

Authors:  Chiara Bruckmann; Simone Tamburri; Valentina De Lorenzi; Nunzianna Doti; Alessandra Monti; Lisa Mathiasen; Angela Cattaneo; Menotti Ruvo; Angela Bachi; Francesco Blasi
Journal:  Sci Rep       Date:  2020-10-08       Impact factor: 4.379

Review 3.  Targeting Chromatin Complexes in Myeloid Malignancies and Beyond: From Basic Mechanisms to Clinical Innovation.

Authors:  Florian Perner; Scott A Armstrong
Journal:  Cells       Date:  2020-12-21       Impact factor: 6.600

Review 4.  Treatment of AML Relapse After Allo-HCT.

Authors:  Jonathan A Webster; Leo Luznik; Ivana Gojo
Journal:  Front Oncol       Date:  2021-12-16       Impact factor: 6.244

Review 5.  Current status and future perspectives in targeted therapy of NPM1-mutated AML.

Authors:  Roberta Ranieri; Giulia Pianigiani; Sofia Sciabolacci; Vincenzo Maria Perriello; Andrea Marra; Valeria Cardinali; Sara Pierangeli; Francesca Milano; Ilaria Gionfriddo; Lorenzo Brunetti; Maria Paola Martelli; Brunangelo Falini
Journal:  Leukemia       Date:  2022-08-25       Impact factor: 12.883

Review 6.  MEIS1 and its potential as a cancer therapeutic target (Review).

Authors:  Maozhong Yao; Yong Gu; Zhaoxin Yang; Keyan Zhong; Zhanjuan Chen
Journal:  Int J Mol Med       Date:  2021-07-28       Impact factor: 4.101
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.